Viewing Study NCT02416232


Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-01-05 @ 6:01 PM
Study NCT ID: NCT02416232
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2017-08-15
First Post: 2015-04-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Sponsor: GlaxoSmithKline
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module